Patient Advocate Insider: From the Desk of Karen Selby, R.N.Treatment & Doctors
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Selby, K. (2020, October 16). Patient Advocate Insider: From the Desk of Karen Selby, R.N.. Asbestos.com. Retrieved January 26, 2023, from https://www.asbestos.com/blog/2012/04/26/karen-selby-insider/
Selby, Karen. "Patient Advocate Insider: From the Desk of Karen Selby, R.N.." Asbestos.com, 16 Oct 2020, https://www.asbestos.com/blog/2012/04/26/karen-selby-insider/.
Selby, Karen. "Patient Advocate Insider: From the Desk of Karen Selby, R.N.." Asbestos.com. Last modified October 16, 2020. https://www.asbestos.com/blog/2012/04/26/karen-selby-insider/.
I had a patient’s daughter e-mail me last week to ask about a new drug she saw on a website about mesothelioma. She wanted my thoughts on Immunotherapy.
The drug in question was Onconase. She asked her mother’s oncologist about it, and she said the doctor told her he had never heard of it.
I suspect the oncologist had not heard of it because Onconase is still being researched and only available through clinical trials. According to the website Ranpirnase.org, ranpirnase is the generic name for Onconase, the drug it is a ribonucleic enzyme which catalyzes the breakdown of RNA.
RNA is one of the three major macromolecules (along with DNA and proteins) present in all forms of life. The role of RNA is complicated but it plays a role in accelerating a chemical change. Basically, it’s created from an enzyme found originally in frogs that speeds up the body’s ability to destroy a cancer cell or stop it from dividing.
Onconase is in its final stages of clinical trials and is not yet approved by the U.S. Food and Drug Administration (FDA). Unfortunately, now that the girl’s mother has started treatment, she probably won’t be eligible to take part in a clinical trial until she completes her current round of treatment series.
The reason for a clinical trial is to see how patients respond to a specific drug or treatment. Doctors who run trials want to obtain the most accurate data. They often prefer participants not to be involved in any other treatment. (Other drugs or supplements in the body may skew the data they are trying to obtain.)
In fact, some studies are not open to patients that have had any prior treatment at all. This particular one is, just not while you are in the middle of another treatment.
As for immunotherapy, it is geared toward making the immune system recognize antigens on cancer cells as being foreign, which allows the immune system to destroy those cells.
There is some question whether immunotherapy offers results that were originally anticipated, and it is still being researched.
The good news is that these trials continue to obtain government funding. I feel that because funding of these immunotherapy trials continues to happen, this must mean that there are enough positive results to warrant hopeful news for our mesothelioma patients.
The other good news is that new trials are being undertaken all the time. There are teams of doctors and researchers pushing to cure mesothelioma.
If you would like to learn more about clinical trial options, contact me. I’d be happy to do some research to see if there are opportunities that suit your individual needs.